Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria
- PMID: 9493491
Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria
Abstract
Some women experience premenstrual mood symptoms that severely disrupt their lives and relationships. These women often require pharmacologic treatment. Selective serotonin reuptake inhibitors, particularly daily fluoxetine, have been proven superior to placebo in several randomized controlled trials. Twenty-four women with confirmed premenstrual dysphoric disorder (PMDD) and with a history of affective disorders or alcoholism were treated with fluoxetine 20 mg/day (continuous), and 24 women with PMDD and no psychiatric history were treated with fluoxetine 20 mg/day for 14 days premenstrually only (intermittent). Both groups received treatment for three menstrual cycles. Sixteen women (66.7%) in the continuous dosing group and 18 women (75.0%) in the intermittent group were classified as treatment responders. Intermittent dosing of fluoxetine seems to be effective and mostly free of side effects in women with PMDD and, therefore, may offer an attractive treatment option for a disorder that is itself intermittent.
Similar articles
-
Premenstrual dysphoria and the serotonin system: pathophysiology and treatment.J Clin Psychiatry. 2000;61 Suppl 12:17-21. J Clin Psychiatry. 2000. PMID: 11041380 Review.
-
The role of fluoxetine in the treatment of premenstrual dysphoric disorder.Clin Ther. 1999 Apr;21(4):615-33; discussion 613. doi: 10.1016/S0149-2918(00)88315-0. Clin Ther. 1999. PMID: 10363729 Review.
-
Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder.Expert Opin Pharmacother. 2002 Jul;3(7):979-91. doi: 10.1517/14656566.3.7.979. Expert Opin Pharmacother. 2002. PMID: 12083997 Review.
-
SSRIs for premenstrual dysphoric disorder.Drug Ther Bull. 2002 Sep;40(9):70-2. doi: 10.1136/dtb.2002.40970. Drug Ther Bull. 2002. PMID: 12298224 Review.
-
Fluoxetine in the treatment of premenstrual dysphoric disorder.Ann Pharmacother. 2002 Apr;36(4):713-7. doi: 10.1345/aph.1A265. Ann Pharmacother. 2002. PMID: 11918525 Review.
Cited by
-
Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature.CNS Drug Rev. 2004 Spring;10(1):45-76. doi: 10.1111/j.1527-3458.2004.tb00003.x. CNS Drug Rev. 2004. PMID: 14978513 Free PMC article. Review.
-
Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial.JAMA Psychiatry. 2015 Oct;72(10):1037-44. doi: 10.1001/jamapsychiatry.2015.1472. JAMA Psychiatry. 2015. PMID: 26351969 Free PMC article. Clinical Trial.
-
Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder.CNS Drugs. 2004;18(7):453-68. doi: 10.2165/00023210-200418070-00004. CNS Drugs. 2004. PMID: 15139800 Review.
-
Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard?Drugs. 2002;62(13):1869-85. doi: 10.2165/00003495-200262130-00004. Drugs. 2002. PMID: 12215058 Review.
-
The role of central serotonergic dysfunction in the aetiology of premenstrual dysphoric disorder: therapeutic implications.CNS Drugs. 2001;15(4):277-85. doi: 10.2165/00023210-200115040-00003. CNS Drugs. 2001. PMID: 11463133 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical